Aim: This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Patients & methods: Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. Results: SPMs occurred in 308 German (n = 2360), 273 Swedish (n = 2849) and 172 US (n = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4–88.4), 101.7 (95% CI: 90.3–114.5) and 59 (95% CI: 50–68) per 1000 person-years in German, Swedish and US cohorts, respectively. Conclusion: These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). • Provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
MedlineGoogle Scholar
2. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J. Urol. 175(4), 1337–1340 (2006).
MedlineGoogle Scholar
3. Lange P, Vessella R. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev. 17, 331–336 (1999).
CASGoogle Scholar
4. Riihimaki M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Clinical landscape of cancer metastases. Cancer Med. 7(11), 5534–5542 (2018).
MedlineGoogle Scholar
5. Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 350(16), 1655–1664 (2004).
Medline CASGoogle Scholar
6. Mostaghel EA. Steroid hormone synthetic pathways in prostate cancer. Transl. Androl. Urol. 2(3), 212–227 (2013).
MedlineGoogle Scholar
7. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 11(3), 459–476 (2004).
Medline CASGoogle Scholar
8. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends. Endocrinol. Metab. 21(5), 315–324 (2010).
Medline CASGoogle Scholar
9. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin. Proc. 85(1), 77–86 (2010).
Medline CASGoogle Scholar
10. Katzenwadel A, Wolf P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 367(1), 12–17 (2015).
Medline CASGoogle Scholar
11. Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry De Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat. Rev. 41(7), 588–597 (2015).
Medline CASGoogle Scholar
12. Shore ND, Rai G, Fizazi K, Wilson L, Zhan L. Survival outcomes of pre-metastatic castration-resistant prostate cancer and the burden of developing metastasis: a systematic literature review. J. Clin. Oncol. 36(Suppl. 6), S293 (2018).
Google Scholar
13. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol. 184(1), 162–167 (2010).
MedlineGoogle Scholar
14. Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev. Anticancer Ther. 11(1), 25–28 (2011).
Medline CASGoogle Scholar
15. Di Lorenzo G, D’aniello C, Buonerba C et al. Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 24(1), 84–89 (2013).
MedlineGoogle Scholar
16. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213–223 (2013).
Medline CASGoogle Scholar
17. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995–2005 (2011).
MedlineGoogle Scholar
18. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
Medline CASGoogle Scholar
19. Su VY, Liu CJ, Chen YM et al. Risk of second primary malignancies in lung cancer survivors – the influence of different treatments. Target Oncol. 12(2), 219–227 (2017).
MedlineGoogle Scholar
20. Uprety D, Khanal A, Arjyal L et al. The risk of secondary primary malignancy in early stage differentiated thyroid cancer: a US population-based study. Acta Oncol. 55(11), 1375–1377 (2016).
MedlineGoogle Scholar
21. Areethamsirikul N, Reece DE. The risk of secondary primary malignancies after therapy for multiple myeloma. Leuk. Lymphoma 56(11), 3012–3021 (2015).
MedlineGoogle Scholar
22. Suriano F, Altobelli E, Sergi F, Buscarini M. Bladder cancer after radiotherapy for prostate cancer. Rev. Urol. 15(3), 108–112 (2013).
MedlineGoogle Scholar
23. (NCT02141438) Observational study for the evaluation of long-term safety of radium-223 used for the treatment of metastatic castration resistant prostate cancer (REASSURE) (2020). https://clinicaltrials.gov/ct2/show/NCT02141438
Google Scholar
24. Van Hemelrijck M, Wigertz A, Sandin F et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int. J. Epidemiol. 42(4), 956–967 (2013). • Describes the Prostate Cancer Data Base Sweden, which was analyzed to obtain overall survival and incidence of second primary malignancies in men with metastatic castration-resistant prostate cancer for the Swedish cohort of the study in the current manuscript.
MedlineGoogle Scholar
25. Mehtala J, Zong J, Vassilev Z et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS ONE 15(2), e0227552 (2020). • In this analysis of the Prostate Cancer Data Base Sweden, factors associated with mortality and second primary malignancies in men with bone metastatic prostate cancer and metastatic castration-resistant prostate cancer were investigated.
Medline CASGoogle Scholar
26. Saltus CW, Vassilev ZP, Zong J et al. Incidence of second primary malignancies in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the United States. Prostate Cancer 2019, 4387415 (2019). • Contains the original publication of results from the US cohort, the Surveillance, Epidemiology and End Results-Medicare database, that are summarized in the current manuscript.
MedlineGoogle Scholar
27. Measures that are limited or not available in the data (2020). https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html#13
Google Scholar
28. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am. J. Epidemiol. 147(8), 783–790 (1998).
Medline CASGoogle Scholar
29. Saltus C, Harris D, Calingaert B et al. Identification of second primary malignancies (SPM) in men with castration-resistant prostate cancer (CRPC) in SEER-Medicare data. Pharmacoepidemiol. Drug Saf. 26, 294 (2017).
MedlineGoogle Scholar
30. Sartor O, de Bono JS. Metastatic prostate cancer. N. Engl. J. Med. 378(17), 1653–1654 (2018).
MedlineGoogle Scholar
31. Tomic K, Berglund A, Robinson D et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 54(2), 158–163 (2015).
MedlineGoogle Scholar
32. Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology 23(3), 288–295 (2009).
MedlineGoogle Scholar
33. Schink T, Garbe E. Assessment of the representativity of in-patient hospital diagnoses in the German Pharmacoepidemiological Research Database. Gesundheitswesen 72(08/09), P10 (2010). • Assesses the representativity of in-patient hospital diagnoses in the German Pharmacoepidemiological Research Database. This database was used as the German cohort of the study in the current manuscript.
MedlineGoogle Scholar
34. Schink T, Garbe E. Representativity of dispensations of non-steroidal anti-inflammatory drugs (NSAIDs) in the German Pharmacoepidemiological Research Database. Gesundheitswesen 72(08/09), V111 (2010).
Google Scholar
35. Gillessen S, Attard G, Beer TM et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur. Urol. 73(2), 178–211 (2018).
MedlineGoogle Scholar
36. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/
Google Scholar
37. Donin N, Filson C, Drakaki A et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122(19), 3075–3086 (2016).
MedlineGoogle Scholar
38. Burton AJ, Tilling KM, Holly JM et al. Metabolic imbalance and prostate cancer progression. Int. J. Mol. Epidemiol. Genet. 1(4), 248–271 (2010).
Medline CASGoogle Scholar
39. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352–360 (2017).
Medline CASGoogle Scholar
40. James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377(4), 338–351 (2017).
Medline CASGoogle Scholar
41. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163–1177 (2016).
Medline CASGoogle Scholar
42. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015).
Medline CASGoogle Scholar
43. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).
Medline CASGoogle Scholar
44. Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13–24 (2019).
Medline CASGoogle Scholar
45. Crawley D, Garmo H, Rudman S et al. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open 8(3), e020787 (2018).
MedlineGoogle Scholar
46. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am. J. Epidemiol. 174(7), 860–870 (2011).
MedlineGoogle Scholar

Vol. 16, No. 25

Supplemental Materials

Metrics

Downloaded 1,294 times

History

Received 14 April 2020

Accepted 21 May 2020

Published online 9 June 2020

Published in print September 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2020-0315

Author contributions

J Zong was responsible for the individual studies’ conception and design. ZP Vassilev, M Soriano Gabarró, JA Kaye, CW Saltus, O Riedel, O Scholle, J Mehtälä, P Korhonen, E Garbe and J Zong were responsible for data acquisition and analysis, as well as drafting and revision of the manuscript.

Acknowledgments

The authors would like to thank AOK Bremen/Bremerhaven and Die Techniker (TK) that provided data for this study; NCI, which provided access to linked SEER-Medicare data; and PCBaSe, which provided data from the Swedish National Health Register linkage. The authors would also like to thank H Khanfir for assistance in analyzing the Swedish data and B Calingaert for analyzing the US data.

Disclaimer

The main results and sensitivity analyses of the US study have previously been published in references [26] and [29]. The main results and sensitivity analyses of the Swedish study have previously been published in reference [25].

Data & protocol sharing statement

Individual participant data that underlie the results reported in this article will not be shared. In Germany, use of personal data is protected by the Federal Data Protection Act, and particularly the use of claims data for research is regulated by the Code of Social Law. Researchers have to apply for a project-specific permit from the statutory health insurance providers as well as their governing authorities. The use of the data on which this publication is based was only allowed for BIPS employees within the framework of the specified project and limited to a predefined time span. Researchers who want to access the data on which this publication is based need to ask for new approval by the statutory health insurance providers and their respective authorities.

Individual participant data from the Swedish study cannot be directly shared per the data use agreement between EPID Research and Uppsala County Council. The Steering Group of the National Prostate Cancer Register coordinates research projects within the PCBaSe framework and can be contacted in order to submit a request for data. For further information, see http://npcr.se/npcr/medarbetare/

Individual participant data from the US study cannot be shared per the data use agreement between RTI-HS and NCI.

The three study protocols for each of the cohorts are publicly available in the EU PAS Register of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), under EU PAS Register numbers EUPAS12665 (GePaRD), EUPAS33448 (PCBaSe) and EUPAS13602 (SEER program).

Financial & competing interests disclosure

O Riedel and O Scholle are current employees and E Garbe is a former employee of the Leibniz Institute for Prevention Research and Epidemiology – BIPS; J Mehtälä and P Korhonen are employees of EPID Research Oy; and C Saltus and J Kaye are employees of RTI Health Solutions, all of which received funding from Bayer AG to conduct these studies. BIPS, EPID Research and RTI Health Solutions designed their respective studies, acquired the data, conducted the analyses, interpreted study results and decided to submit the article for publication with input from Bayer. Z Vassilev, J Zong and M Soriano-Gabarró are employees of Bayer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The studies and this report were funded by Bayer AG; claimed by both brand and generic name.

We thank Katherine Mezic, PhD (Chameleon Communications International with funding from Bayer AG) for editorial assistance in the preparation of this report.

Ethical conduct of research

The authors state that the studies within this work were conducted using data from the GePaRD (Germany), PCBaSe (Sweden; with data use agreement on 28 November 2016) and NCI’s SEER program (USA). Studies were guided by data use agreements between the statutory health insurance providers, the respective governing authorities and the Leibniz Institute for Prevention Research and Epidemiology – BIPS; between the PCBaSE and EPID Research Oy; and between NCI and RTI Health Solutions. According to the Ethics Committee of the University of Bremen, studies based on GePaRD are exempt from institutional review board review. Swedish and US studies were reviewed by their respective institutional review boards, receiving exemptions on 24 October 2016, and 23 February 2016.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PDF download